Table 2 Top 15 overrepresented pathways associated with long-term PM2.5 exposure for girls and boys
Sex | Pathway | Effective/total size | # ↓ genes | Contributing genes | P-value |
|---|---|---|---|---|---|
Girls | Â | Â | Â | Â | Â |
Generic Transcription Pathwaya | 367/478 | 80 | Top 5 out of 33 significant genes: ZNF124↑; MED16↑; KRBA1↑; ZNF205↓; ZNF720↑ | 3.0E-06 | |
Defensins | 19/53 | 15 | ART1↓;DEFA3↓; DEFB1↓;DEFB128↑;DEFA4↓ | 5.7E-04 | |
Binding and Uptake of Ligands by Scavenger Receptorsa | 28/43 | 15 | APOA1↓; HPR↓; HP↓; HBA2↑; FTL↑ | 3.6E-03 | |
agrin in postsynaptic differentiation | 39/47 | 18 | EGFR↑; PTK2↑; UTRN↑; ITGB1↑; CHRM1↓ | 1.5E-02 | |
JAK-STATa | 39/43 | 15 | PTK2↑; ESR1↓; ZAP70↑;PDK1↑; ITGB1↑ | 1.5E-02 | |
ATM Signaling Pathwaya | 15/18 | 7 | ATM↑;ATF2↑;RAD51↓ | 1.7E-02 | |
Integrated Pancreatic Cancer Pathway | 141/165 | 62 | SERPINB10↓;CAMP↓;RAD51↓;TYMS↓;INHBA↓; NTRK1↓;ATM↑;EGFR↑ | 1.8E-02 | |
Transcriptional misregulation in cancer - Homo sapiens (human) | 146/179 | 73 | CEBPE↓; CDKN2C↓; EWSR1↑; DEFA3↓; HIST1H3J↓; PTK2↑; ASPSCR1↓; MPO↓; NTRK1↓; ELANE↓; ATM↑ | 2.3E-02 | |
BARD1 signaling events | 29/29 | 17 | RAD51↓;ATM↑;EWSR1↑;UBE2D3↑ | 2.3E-02 | |
Gastric cancer network 2 | 29/32 | 9 | CACYBP↑;AHCTF1↑;EGFR↑;BRIX1↑ | 2.3E-02 | |
Extracellular matrix organization | 167/275 | 92 | ITGB1↑; ELANE↓; MMP17↓; LTBP3↑; PLOD1↑; CTSG↓; CEACAM1↓; MMP8↓; CEACAM6↓; CEACAM8↓; COL17A1↓ | 2.5E-02 | |
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | 32/45 | 15 | CTSG↓;EGFR↑;ELANE↓;ITGB1↑ | 3.2E-02 | |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 20/21 | 3 | UBA52↑; TGIF2↑; PPM1A↑ | 3.8E-02 | |
JAK-STAT-Core | 67/104 | 29 | IL11RA↑; IL12RB1↑; STAT4↑; MPL↑; EGFR↑; IL6ST↑ | 4.1E-02 | |
Boys | Â | Â | Â | Â | Â |
TNF receptor signaling pathway | 44/48 | 29 | IKBKB↑; MAP4K5↑; TAB2↑; TAB1↓; MAP2K3↑; TNIK↓; TNF↓; IKBKG↑; GNB2L1↓ | 4.8E-03 | |
Mercaptopurine Action Pathway | 38/47 | 21 | ATIC↓; PAICS↓; TPMT↓; APRT↓; ITPA↓; ADA↓; ABCC4↓; ADSL↓ | 6.5E-03 | |
Primary immunodeficiency - Homo sapiens (human) | 32/36 | 25 | ICOS↓; ORAI1↓; CD40LG↓; IKBKG↑; ADA↓; CD3D↓; LCK↓ | 8.6E-03 | |
the co-stimulatory signal during t-cell activation | 18/21 | 13 | CTLA4↓; ICOS↓; CD3D↓; LCK↓; ITK↓ | 9.0E-03 | |
FCERI mediated NF-kB activationa | 19/63 | 13 | IKBKB↑; TAB2↑; TAB1↓; RASGRP1↓; IKBKG↑ | 1.1E-02 | |
p73 transcription factor network | 68/81 | 38 | GNB2L1↓; PFDN5↑; PLPP1↓; UBE4B↑; TP73↓; BAK1↓; FOXO3↑; ADA↓; MDM2↑; BIN1↓; MYC↓ | 1.2E-02 | |
Axon guidance - Homo sapiens (human)a | 88/127 | 57 | EPHB2↓; EPHB3↓; ROBO2↓; PPP3R1↑; ROBO3↓; EFNA4↓; EFNA3↓; ROCK1↑; EPHA1↓; ITGB1↑; RGS3↓; ABLIM1↓; SEMA4C↓ | 1.4E-02 | |
Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics | 28/32 | 22 | PRPS1↓; TPMT↓; NT5E↓; ITPA↓; ADA↓; ABCC4↑ | 1.6E-02 | |
T cell receptor signaling pathway - Homo sapiens (human) | 91/104 | 59 | DLG1↑; CTLA4↓; ICOS↓; RASGRP1↓; CD40LG↓; ITK↓; PPP3R1↑; IKBKB↑; TNF↓; CDK4↓; IKBKG↑; CD3D↓; LCK↓ | 1.8E-02 | |
Oncogene Induced Senescencea | 29/31 | 13 | TP53↓; E2F2↑; CDK4↓; TFDP1↑; MDM2↑; AGO3↑ | 1.9E-02 | |
Regulation of nuclear beta catenin signaling and target gene transcription | 64/81 | 39 | TCF7↓; HDAC2↓; TBL1XR1↑; AES↓; CAMK4↓; TNIK↓; APC↑; MYC↓; LEF1↓; AXIN2↓ | 2.1E-02 | |
TP53 Network | 15/18 | 7 | MDM2↑; TP53↓; MYC↓; TP73↓ | 2.2E-02 | |
Bladder Cancer | 23/26 | 14 | CDK4↓; TYMP↓; MDM2↑; TP53↓; MYC↓ | 2.6E-02 | |
Stimuli-sensing channels | 68/102 | 38 | TRPV6↓; CLCN3↑; WNK2↓; TRPM5↓; CLCN7↑; ANO10↓; TPCN1↑; BEST4↓; WWP1↓; WNK1↑ | 3.0E-02 | |
Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human) | 41/51 | 23 | NEFH↓; PPP3R1↑; TOMM40↓; TNF↓; BCL2L1↑; MAP2K3↑; TP53↓ | 3.2E-02 |